Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | CTSA | P10619 | 12/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232579 | 1.00 | KMT2A (0.54) | KMT2AGAACTSAL3MBTL1ALDH1A1 | |
| SCHEMBL9224006 | 0.89 | KMT2A (0.52) | KMT2AGAACTSAL3MBTL1ALDH1A1 | |
| SCHEMBL2789512 | 0.89 | KMT2A (0.54) | KMT2AGAAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL9222644 | 0.85 | POLB (0.55) | KMT2ACTSAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL9228033 | 0.84 | NPSR1 (0.54) | CTSAL3MBTL1ALDH1A1MAPTHTT | |
| SCHEMBL9222660 | 0.84 | KMT2A (0.50) | KMT2AGAAL3MBTL1ALDH1A1MAPT | |
| SCHEMBL1990348 | 0.84 | PTGER1 (0.51) | KMT2AGAACTSAL3MBTL1MAPT | |
| SCHEMBL1990350 | 0.84 | PTGER1 (0.51) | KMT2AGAACTSAL3MBTL1MAPT | |
| SCHEMBL5198568 | 0.83 | NPSR1 (0.47) | KMT2AGAACTSAL3MBTL1ALDH1A1 | |
| SCHEMBL13196108 | 0.83 | KMT2A (0.48) | KMT2AGAACTSAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010092500-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-08-19 | — | — | WO | claimed |
| WO-2010046801-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-04-29 | — | — | WO | claimed |
| US-20120041235-A1 | PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2012-02-16 | — | — | US | disclosed |
| EP-2398765-A1 | IMPROVED PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF | Pharmathen S.A. (GR) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010046801-A3 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010094292-A1 | IMPROVED PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF | PHARMATHEN S.A. (GR) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010092500-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092500-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010046801-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046801-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046801-A2 | A PROCESS FOR THE PREPARATION OF TOLTERODINE TARTRATE | ALEMBIC LIMITED (IN) | 2010-04-29 | — | — | WO | disclosed |
| US-7358399-B2 | Process for the preparation of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl-propaneamine | CHEMI SPA (IT) | 2008-04-15 | — | — | US | disclosed |
| US-20060281805-A1 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-12-14 | — | — | US | disclosed |
| EP-1618091-A1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004089898-A1 | SUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | disclosed |
| US-5382600-A | 3,3-diphenylpropylamines and pharmaceutical compositions thereof | PHARMACIA AKTIEBOLAG (SE) | 1995-01-17 | — | — | US | disclosed |
| EP-0325571-B1 | NEW AMINES, THEIR USE AND PREPARATION | Kabi Pharmacia AB (SE) | 1991-08-07 | — | — | EP | disclosed |
| EP-0354234-A1 | NEW AMINES, THEIR USE AND PREPARATION | KabiVitrum AB (SE) | 1990-02-14 | — | — | EP | disclosed |
| WO-1989006644-A1 | NEW AMINES, THEIR USE AND PREPARATION | KABIVITRUM AB (SE) | 1989-07-27 | — | — | WO | disclosed |
| EP-0325571-A1 | New amines, their use and preparation | Kabi Pharmacia AB (SE) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041235-A1 | PROCESS FOR THE PREPARATION OF (R)-2-(3-DIISOPROPYLAMINO)-1-PHENYLPROPYL)-4METHYLPHENOL AND SALTS THEREOF | PAH, UGT1A7, MLN | KMT2A 4050/4885GAA 1407/4885CTSA 2909/4885 |
| US-20060281805-A1 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | KMT2A 3238/4885GAA 2894/4885CTSA 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.